5-(1-甲基-1H-咪唑-2-基)-1,3-恶唑 | 681135-49-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(1-甲基-1H-咪唑-2-基)-1,3-恶唑
• 英文名称: 5-(1-methyl-1H-imidazol-2-yl)oxazole
• 英文别名: 5-(1-methylimidazol-2-yl)-1,3-oxazole
• CAS: 681135-49-9
• 化学式: C₇H₇N₃O
• mdl: MFCD08668018
• 分子量: 149.15
• InChiKey: RDVIQCGECBBHNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Inhibitors of fatty acid amide hydrolase
  申请人：Boger L Dale

  公开号：US20060111359A1

  公开（公告）日：2006-05-25

  Improved competitive inhibitors of FAAH employ an α-keto heterocyclic pharmacophore and a binding subunit having a ?-unsaturation. The α-keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain. The improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that have alkyl or aryl substituents at their 4 and/or 5 positions. The improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.

  改进的FAAH竞争性抑制剂采用α-酮杂环药基和具有?-不饱和度的结合亚单位。α-酮杂环药基和结合亚单位相互连接，最好通过一个碳氢链。改进之处在于使用从噁唑、噁二唑、噻唑和噻二唑中选择的具有烷基或芳基取代基的杂环药基，其在其4和/或5位置。改进的FAAH竞争性抑制剂显示出比传统FAAH竞争性抑制剂更强的活性。
• EP1549624A4
  申请人：——

  公开号：EP1549624A4

  公开（公告）日：2006-09-20
• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：The Scripps Research Institute

  公开号：EP1549624A2

  公开（公告）日：2005-07-06
• US7662971B2
  申请人：——

  公开号：US7662971B2

  公开（公告）日：2010-02-16
• [EN] INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] INHIBITEURS D'AMIDE HYDROLASE D'ACIDE GRAS
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2004033652A2

  公开（公告）日：2004-04-22

  Improved competitive inhibitors of FAAH employ an α-keto heterocyclic pharmacophore and a binding subunit having a ?-unsaturation. The α-keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain. The improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that have alkyl or aryl substituents at their 4 and/or 5 positions. The improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.